263 results about "Drug release" patented technology

The present invention provides a solid dispersion of compound 1 or a pharmaceutical salt thereof, comprising the compound 1 or the pharmaceutical salt thereof as an active ingredient and a carrier material, wherein the carrier material is selected from one, two, or more of polyvinylpyrrolidone (PVP), copovidone, polyvinylpyrrolidone-vinyl acetate copolymer, hydroxypropyl methylcellulose acetate succinate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl methylcellulose, polyethylene glycol, and ethyl cellulose, enabling the drug to have good stability, dissolution, and therapeutic effects. The formulation of the present invention provides rapid drug release and can reduce the oral burden of large-dose tablets on menopausal patients, thereby improving treatment compliance and treatment efficiency.

This application belongs to the field of medical devices and relates to an intraoral drug delivery device. The drug delivery device includes a substrate that can be disposed on a tooth crown. The substrate has a drug storage unit. When the substrate is disposed on the tooth crown, the drug storage unit can release drug outwards. Alternatively, the drug delivery device includes an adhesive layer that can adhere to the tooth crown, the adhesive layer containing a drug mixture. By disposing the substrate on the tooth crown and having the drug storage unit disposed therein, the drug can be released, providing therapeutic or nursing effects to the tooth crown, oral cavity, or body.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

The application belongs to the technical field of medical biomaterials, and particularly relates to an interpenetrating network polymer based on phosphorylcholine polymer and a preparation method and application thereof. The application provides a sequential interpenetrating network method, which comprises the following steps: preparing a monomer infiltration solution containing phosphorylcholine monomer, polyethylene glycol methacrylate, dimethylaminoethyl methacrylate, butyl methacrylate, hydroxyethyl methacrylate, ethylene glycol methacrylate, a crosslinking agent and an initiator; dipping a high-molecular polymer matrix into the monomer infiltration solution, and performing ultrasonic oscillation treatment to promote the infiltration of monomers into the interior of the matrix; and performing a polymerization reaction to obtain a final product after washing; the material prepared by the application has excellent thermal stability, excellent swelling performance, intelligent pH response drug release capacity and biocompatibility, and is suitable for the fields of biological medicine and cosmetics.

The utility model discloses a kind of human middle hole acupoint patches with double-sided medicine component structure, belong to acupoint patch field, including substrate, the downside of the substrate is provided with medicine release layer, the downside of the medicine release layer is provided with medicine sheet, the upper end of the substrate is provided with first base layer, the upside of the first base layer is glued with covering layer, the upside of the first base layer is provided with first incense piece, the downside of the covering layer is provided with second incense piece;By setting medicine sheet, first incense piece and second incense piece on the upper and lower sides of substrate respectively, so that acupoint patch can be in the meantime in human middle hole, through first incense piece and second incense piece reasonable use the special position of human middle hole, better through human respiration, more fully utilize the comprehensive treatment effect of medicine, aromatic medicine and aromatic essential oil to human body.

The preparation and application of spaced double disulfide bond bridged dimer prodrug and self-assembled nanoparticles thereof belong to the technical field of medicine, and relate to the synthesis of the connection of the spaced double disulfide bond bridged dimer prodrug shown in structural general formula (I) and the construction of the spaced double disulfide bond bridged dimer prodrug shown in structural general formula (II) and self-assembled nanoparticles thereof, and the application thereof in drug delivery. The preparation method is simple and easy to implement, the spaced double disulfide bond bridged dimer prodrug can be self-assembled to form nanoparticles, and has the ability of redox dual response drug release, so that the intelligent response activation of the prodrug in tumor cells can be realized, and the anti-tumor effect and safety of the prodrug are ensured. The anti-tumor effect, pharmacokinetic parameters and safety thereof are superior to those of the prodrug nanoparticles bridged by a single disulfide bond. The present application provides a new strategy for developing a high-efficiency low-toxicity drug delivery system, and meets the urgent needs of high-end chemotherapy preparations in clinical practice.

The present application relates to the technical field of external use patch, disclose a kind of neck shoulder waist leg pain health care patch and its preparation method, the health care patch includes backing layer, ointment layer and anti-adhesion release layer;Ointment layer raw material includes: traditional Chinese medicine extract flow leaching paste, L- (+) -tartaric acid, PVP K30, PEG-400, ternary eutectic solvent, polyacrylate pressure sensitive adhesive matrix and ultrafine medicinal powder.Preparation, after flow leaching paste, tartaric acid etc. are mixed, gel precursor is formed by vacuum dewatering and dealcoholization, swelling is added again with eutectic solvent, and then mixed with pressure sensitive adhesive matrix and medicinal powder high shear, finally coating solidification.The present application constructs physical crosslinking gel network in colloid interior and promotes effective component acid-base salt formation, effectively avoids polar component crystallization precipitation, reduces the skin irritation caused by drug burst release, simultaneously improves the cohesion of ointment, realizes long-acting smooth drug release.

The present application relates to a controllable degradation of siliconized DNA hydrogel and its preparation method and application, the hydrogel is assembled into a three-dimensional network through the DNA structure with single-stranded region in the center and linear DNA structure, and the mechanical properties and thermal stability thereof are improved through in-situ siliconization. The precisely designed single-stranded region can still be recognized and degraded by specific nucleic acid enzyme after siliconization, realizing the accurate control of selective degradation. Taking human umbilical vein endothelial cells as an example, the present application verifies the good biocompatibility of the material, and the present application can be used for cell embedding and release, and is suitable for advanced biological materials, medical, pharmaceutical and other research and application fields such as organoid culture, tissue engineering and controllable drug release.

The invention patent is titled "Dragon and Cypress Gel," belonging to the pharmaceutical category. The main components of Dragon and Cypress Gel are: Phellodendron bark, earthworm, dragon's blood, Oldenlandia diffusa, Sophora flavescens, and Bletilla striata. In recent years, research on cervicitis and cervical lesions has shown good results using external treatments of traditional Chinese medicine. Vaginal cervical medications are characterized by high local drug concentration, low dosage, and safety and effectiveness, receiving high clinical evaluation. The vagina and cervix have abundant capillaries and lymphatic vessels, and lack clearly defined nerve endings, resulting in minimal pain stimulation for patients during administration. This makes it an effective drug release site for specific diseases such as cervicitis and vaginitis. Traditional Chinese medicine gels are a novel type of external preparation of traditional Chinese medicine. They are made by dissolving or uniformly dispersing traditional Chinese medicine in a gel. These gels adhere tightly to the treatment site for a relatively long time, exhibiting good bioadhesion, and are simple to prepare. It is suitable for use on skin, mucous membranes and cavities. It not only avoids the first-pass effect of enzymes and acids in the gastrointestinal tract that exists in oral administration, but also reduces the adverse reactions of drugs. It has the characteristics of good spreadability, non-greasy feeling, easy to wash off, good transdermal absorption, and comfortable use.

This invention discloses a core-shell microneedle with both antibacterial and exudate-absorbing properties, and its preparation method, belonging to the field of microneedle drug delivery systems and acne treatment technology. The microneedle comprises: a core layer containing an exudate-absorbing component for absorbing exudate; and a shell layer covering the core layer, containing a microenvironment-responsive drug delivery unit and antibacterial nanoparticles loaded within the drug delivery unit. The drug delivery unit responds to the microenvironment of the acne lesion by releasing the antibacterial nanoparticles. This invention combines baicalein and surfactant into nanoparticles, loaded into a ROS-responsive shell layer formed by TSPBA and polyvinyl alcohol. Sodium polyglutamate is introduced into the core layer as an exudate-absorbing component. The core-shell microneedle is prepared by a two-step centrifugation method. This invention solves the problems of poor drug permeability, uncontrollable release, and exudate affecting treatment efficacy in traditional acne treatments. It achieves targeted drug release and exudate adsorption synergistic effects on acne lesions, improves drug bioavailability, reduces systemic side effects, and is suitable for the treatment of acne, especially inflammatory and purulent acne.

This invention discloses an antiepileptic magnetically responsive mechanoacturized targeted nanosystem, belonging to the field of biomedicine. The nanosystem, administered intravenously, accumulates in the epileptic focus area under the guidance of an external gradient magnetic field. Further, an alternating magnetic field triggers internal mechanoacturized units to generate mechanical movements such as rotation or vibration, thereby inducing structural changes in the drug-loading unit and achieving local release of the antiepileptic drug. The nanosystem can be further integrated with a blood-brain barrier-crossing targeting modification module and a monitoring module to improve lesion targeting and drug release controllability, and help reduce systemic exposure. This nanosystem can be used for the prevention and intervention of epilepsy.

The invention belongs to the field of medical instruments, and discloses a medical silica gel dressing fixing adhesive tape which comprises an adhesive tape body, and the adhesive tape body sequentially comprises a carrier layer, a silica gel adhesive layer and a stripping liner from outside to inside; the carrier layer is made of an elastic breathable material, and the silica gel adhesive layer is made of medical-grade organic silica gel; a plurality of first microcapsules are dispersed in the silica gel adhesive layer, the first microcapsules are drug-loaded microcapsules, and wall materials of the drug-loaded microcapsules are made of materials responding to the pH value, enzyme concentration or temperature change of a wound environment. Enzyme or ions are released after the second microcapsule is broken, the wall material of the first microcapsule is actively degraded, cascade response of'exudate increase-developing prompt-drug accelerated release 'is realized, a large amount of drugs are quickly released when the exudate appears, and infection or inflammation is effectively controlled.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

A system and method are provided for remotely supervised preparation, verification, and controlled dispensing of medication doses at geographically distributed remote dispensing units. A recipient and a supervisor are authenticated. A real-time audiovisual session is established between the recipient and at least the supervisor, and additional authenticated participants may join without authority to actuate dose release. The system receives an electronic medication order and corresponding label data originating from an external clinical information system and authorizes preparation of doses at the remote dispensing unit based on the order. Prior to any release, verification data is presented to the supervisor. A controlled mechanical transfer mechanism is actuated to release a prepared dose to the recipient only after verification and affirmative authorization by an authenticated supervisor. The disclosed systems and methods are applicable to controlled substances and other medications requiring supervised dispensing.

This invention belongs to the field of medical technology, specifically relating to a tandem controlled-release nucleic acid nanoprobe composite hydrogel and its application in the diagnosis and treatment of wound infections. First, the invention modifies the surface of gold nanoparticles with nucleic acid sequences via Au-S bonds to prepare a DNA-gold nanoparticle probe (NAFP), achieving highly specific detection of sulfides, a wound infection marker. Then, using mesoporous silica as a carrier, an antibacterial drug is loaded, constructing mesoporous silica D@MSNs loaded with a double-stranded DNA molecule valve-type bactericide. Subsequently, the NAFP and D@MSNs are formulated into a gel to obtain a therapeutic dressing. This dressing can trigger conformational changes in nucleic acids through infection markers, achieving precise matching of drug release to the degree of infection, thereby enabling in-situ detection of bacteria. It also possesses highly efficient antibacterial activity, physical protection, and moisturizing functions. The dressing is easy to operate, has low clinical translation costs, and is suitable for the diagnosis and treatment of acute and chronic wound infections, showing broad application prospects.

This invention provides a nanocomposite material with a core-shell structure. The nanocomposite material comprises: ZnO nanoparticles as the core; mesoporous silica as the shell coating the surface of the ZnO nanoparticles; an antibiotic loaded within the pores of the mesoporous silica; hyperbranched polylysine modified on the surface of the mesoporous silica; and a pH-responsive coating material as the outermost layer. The nanocomposite material provided by this invention enables precise targeted drug release in the colon, simultaneously addressing multiple factors leading to CDI recurrence, such as biofilm protection, spore storage, microbial disruption, and mucosal damage, through a sequential synergistic mechanism of "membrane disruption-bactericidal-spore inhibition-repair," thereby improving treatment efficacy.

The present disclosure relates generally to bioactive releasing membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the disclosure relates to novel bioactive releasing membranes, to devices and implantable devices including these membranes, methods for forming the bioactive releasing membranes on or around the implantable devices, and to methods for monitoring analyte levels in a biological fluid sample using an implantable analyte detection device.

Orally administered pharmaceutical compositions comprising incretin or its analogues or derivatives are presented, which allow for prolonged glycemic control. The formulations presented herein incorporate a self-emulsifying drug delivery system (SEDDS). Advantageously, such formulations provide protection in the upper gastrointestinal tract from proteolytic conditions while allowing for efficient drug release and absorption in the lower gastrointestinal tract.

This invention belongs to the field of biomedical technology, specifically disclosing a nanomicelle FluDox-MIC, its preparation method, and its uses. This nanomicelle is formed by the self-assembly of flumatinib and doxorubicin co-loaded in mPEG-DSPE, exhibiting pH-responsive release properties. Upon entering the tumor microenvironment, it releases the drug. The released flumatinib induces the degradation of the poliovirus receptor (PVR / CD155), relieving its inhibitory signal on NK cells and reactivating innate immune surveillance. Simultaneously, low-dose doxorubicin induces significant immunogenic cell death (ICD), initiating and amplifying tumor-specific T cell-mediated adaptive immunity. Through the synergistic activation of innate and adaptive immunity, the nanomicelle of this invention can effectively inhibit melanoma growth and overcome immunotherapy resistance, showing promising clinical application prospects.

The application discloses a kind of attenuated salmonella load adjuvant nano combination medicine, the combination medicine is modified to bacterial surface by means of amino and carboxyl condensation reaction, adamantane is simultaneously modified to adjuvant nano medicine surface using diselenium dynamic bond, then the host-guest interaction of adamantane and cyclodextrin is used to assemble two, and then nano medicine is stably combined on the surface of attenuated salmonella.Diselenium dynamic bond can be broken by ultrasound response, so as to realize the effect of drug release.This combination medicine has the tumor targeting enrichment ability of bacteria and the release characteristics of adjuvant nanoparticles under the action of ultrasonic wave, can realize targeted delivery and deep penetration in tumor tissue, and obtain significant tumor inhibition effect under ultrasonic stimulation.The experimental results show that the combination medicine exhibits good therapeutic effect in inhibiting tumor growth, and has excellent biological safety.

This invention relates to the field of medical device technology and provides a flexible self-powered oral diagnostic and treatment device and its preparation method. The device includes a flexible conductive porous microneedle, a flexible microfluidic module, a flexible triboelectric nanogenerator, and a flexible transparent dental crown. The flexible conductive porous microneedle is used to extract gingival crevicular fluid, and its surface has multiple rings of needles at different heights. The flexible microfluidic module incorporates a microchannel structure and a detection unit to analyze biomarkers in the gingival crevicular fluid. The flexible triboelectric nanogenerator converts the mechanical energy of oral motion into electrical energy to provide exogenous electrical stimulation and achieve electrically controlled drug release. This device enables real-time monitoring, diagnosis, and treatment of the oral microenvironment, and has advantages such as self-powered operation, good fit, and discreet comfort, making it suitable for closed-loop management of oral diseases such as periodontitis.

The application discloses a kind of compound oral muscarine antipsychotic drug compositions and preparation method thereof, belong to pharmaceutical composition technical field, its technical scheme main point is a kind of compound oral muscarine antipsychotic drug compositions, the pharmaceutical composition is the composition containing two active ingredients, the composition containing two active ingredients is the combination of xanthomelin tartrate microtablet and trospium chloride microtablet, after two active ingredients are made into microtablet respectively, while guaranteeing that product can be released faster, can also increase the time of drug retention in stomach, significantly increase the penetration absorption of drug in body, reduce the fluctuation of blood drug concentration caused by the inconsistent drug release absorption behavior after each administration, so as to better play a role in body, in addition, the technical scheme in the application does not use complex production process, reduces the process development threshold, significantly increases the process reproducibility and stability.

The application discloses a lung hole stent and a preparation method and application thereof. The preparation method of the lung hole stent comprises the following steps: S1, a modified polycaprolactone material is processed into a stent precursor, the stent precursor is soaked in water, taken out, and a stent body is obtained; and S2, the stent body is soaked with a gel precursor solution, and then light curing is carried out, so that the lung hole stent is obtained. The lung hole stent has good drug release capacity and antibacterial capacity, and under the action of repeated mechanical stress caused by periodic expansion and contraction movement, the stent body is not prone to breakage, and the drug-loaded gel is not prone to falling off, so that the lung hole stent can be applied to the scene of lung cavity disease treatment.

The application provides a minimally invasive intracerebral passive adhering brain-computer interface system based on a neuroendoscope, a minimally invasive neuroendoscope implanting module provides a channel and a visual field, and is an operation entrance of the system; a flexible passive chip is a function execution core, signal acquisition, stimulation or drug release are realized; a fixing and adhering module provides structural stability, and reliable long-term operation is ensured; and an external energy / signal coupling module constitutes an energy and information interaction interface, and closed loop control and feedback of the system are realized. Through space position, energy transmission and signal channels, the four modules form a multi-layer cooperative system, and finally precise implantation, stable work and remote control of the intracerebral flexible function chip are realized. The application adopts the above-mentioned minimally invasive intracerebral passive adhering brain-computer interface system based on a neuroendoscope, has good clinical operability and engineering expandability, and provides a reliable implementation path for local precise treatment, neural regulation and brain-computer interface application of central nervous system diseases.

This invention belongs to the field of DNA hydrogel technology, specifically relating to a VEGF-responsive, on-demand release smart DNA hydrogel of glycyrrhizin, its preparation method, and its applications. This invention constructs a VEGF-responsive smart DNA hydrogel, efficiently encapsulating glycyrrhizin within a three-dimensional gel network, utilizing the high expression of VEGF in the tumor microenvironment to trigger on-demand drug release. This invention achieves precise on-demand release of glycyrrhizin, significantly improving drug utilization efficiency and reducing systemic toxicity. Simultaneously, the VEGF aptamer introduced into the system can specifically bind to and neutralize free VEGF, blocking angiogenesis, cutting off tumor nutrient supply, and further inhibiting tumor proliferation and progression, achieving a synergistic effect of intelligent drug delivery and anti-angiogenesis.

The application discloses a preparation method of a novel hierarchical drug release lemon exosome nano preparation and application thereof in brain glioma treatment and belongs to the field of nano medicines. The method comprises the following steps: extracting and purifying lemon exosomes, introducing an anti-glioma drug and a first part of LRP1 up-regulating agent into the inner cavity of the exosomes through electroporation, instantaneously constructing a tumor microenvironment responsive nanogel core to fix the drug, embedding a second part of LRP1 up-regulating agent into the lipid layer of the exosome, modifying Angiopep-2 to realize brain targeting, and obtaining the nano preparation through purification. The preparation has the hierarchical drug release characteristics of outer layer early release and inner cavity delayed release, can improve the efficiency of drug crossing the blood-brain barrier and accumulation at the tumor site, enhance the anti-glioma effect, solves the technical problem that the existing drug loading system is difficult to realize multi-drug phased release, and provides a new strategy for brain glioma treatment.

This invention discloses a biomimetic corncob scaffold with piezoelectric, antibacterial, osteogenic, and healing-promoting functions, comprising: extraction of corncob cellulose nanofibers (CNF); preparation of 3D printing ink; 3D printing of a porous scaffold; loading of antimicrobial peptides and BMP-2 onto a GelMA+PAAM composite hydrogel; and composite preparation of the scaffold and hydrogel. Under external stimulation, the scaffold generates a microcurrent / surface charge, directly disrupting bacterial cell membranes; it avoids drug release and resistance issues, employing a physical mechanism of action with a sustainable response. The microcurrent / electric field generated by the piezoelectric effect simulates the bioelectric environment of natural bone, directly stimulating osteoblast proliferation and differentiation, and promoting mineralization; it mimics the natural anisotropic porous structure of the corncob, facilitating nutrient transport and cell migration; the piezoelectric material itself provides both antibacterial and osteogenic functions, achieving synergistic and unified mechanisms; it is suitable for harsh environments, biodegradable, and has flexible activation methods.

This invention discloses a novel class of peptides for targeted cancer therapy and their corresponding drug or fluorescent dye conjugates, belonging to the field of biomedical technology. These peptides are designed based on the optimized structure of natural LHRH-III, enabling them to specifically bind to and efficiently internalize into tumor cells overexpressing luteinizing hormone-releasing hormone receptor (LHRH-R). After fluorescent conjugation, their targeting ability against 4T1 cells is comparable to that of the classic peptide [D-Lys]. 6 The [-LHRH-I] peptide exhibits comparable to or superior performance and significantly improves cellular internalization efficiency. In vivo distribution studies have shown that its liver accumulation is significantly reduced compared to the control group, effectively lowering the risk of hepatotoxicity. Furthermore, by conjugating the targeting peptide with antitumor drugs (such as camptothecin or doxorubicin) via disulfide linkers, the resulting peptide-drug conjugates (PDCs) demonstrate excellent responsive drug release characteristics and good in vitro and in vivo antitumor activity. The peptides and conjugates provided by this invention have potential application value in cancer targeted therapy and diagnosis with high specificity and low toxicity.